Stifel Nicolaus started coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) in a research report released on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $35.00 price target on the stock.
Rapport Therapeutics Stock Performance
NASDAQ:RAPP opened at $23.30 on Tuesday. Rapport Therapeutics has a twelve month low of $18.00 and a twelve month high of $27.11.
Insider Activity
In related news, Director James Healy acquired 44,032 shares of the stock in a transaction dated Monday, July 1st. The stock was bought at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the purchase, the director now directly owns 40,851 shares of the company’s stock, valued at approximately $1,001,666.52. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
About Rapport Therapeutics
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
- Five stocks we like better than Rapport Therapeutics
- Compound Interest and Why It Matters When Investing
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- How to Calculate Return on Investment (ROI)
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Trading Stocks: RSI and Why it’s Useful
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
